The role of tau in the pathological process and clinical expression of Huntington's disease

Brain

Volumn 138, Issue 7, 2015, Pages 1907-1918

  Vuono, Romina ^a   Winder Rhodes, Sophie ^a,b   De Silva, Rohan ^c   Cisbani, Giulia ^d   Drouin Ouellet, Janelle ^a   Spillantini, Maria G ^a   Cicchetti, Francesca ^d,e   Barker, Roger A ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d Université Laval   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

Author keywords

dementia; Huntington's disease; neurofibrillary tangles; neuropathology; tau

Indexed keywords

HUNTINGTIN; TAU PROTEIN; HTT PROTEIN, HUMAN; MAPT PROTEIN, HUMAN; NERVE PROTEIN;

ADULT; AGED; ARTICLE; AUTOPSY; CLINICAL FEATURE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; HUMAN TISSUE; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MUTANT; NEUROPATHOLOGY; PHENOTYPE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TAUOPATHY; BRAIN; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC ASSOCIATION; GENETICS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; BRAIN; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENETIC ASSOCIATION STUDIES; HUMANS; HUNTINGTON DISEASE; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NERVE TISSUE PROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TAU PROTEINS;

EID: 84930635131     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv107     Document Type: Article

References (42)

1. Anfossi M, Vuono R, Maletta R, Virdee K, Mirabelli M, Colao R, et al. Compound heterozygosity of 2 novel MAPT mutations in frontotemporal dementia. Neurobiol Aging 2011; 32: 757. e1-e11.
2. Baker M, Litvan I, Houlden H, Adamson J, Dickson D, Perez-Tur J, et al. Association of an extended haplotype in the tau gene with progressive supranuclear palsy. Hum Mol Genet 1999; 8: 711-15.
3. Blum D, Herrera F, Francelle L, Mendes T, Basquin M, Obriot H, et al. Mutant huntingtin alters Tau phosphorylation and subcellular distribution. Hum Mol Genet 2015; 24: 76-85.
4. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991; 82: 239-59.
5. Castillo-Carranza DL, Sengupta U, Guerrero-Muñ oz MJ, Lasagna-Reeves CA, Gerson JE, Singh G, et al. Passive immunization with Tau oligomer monoclonal antibody reverses tauopathy phenotypes without affecting hyperphosphorylated neurofibrillary tangles. J Neurosci 2014; 34: 4260-72.
6. Cicchetti F, Lacroix S, Cisbani G, Vallières N, Saint-Pierre M, St-Amour I, et al. Mutant huntingtin is present in neuronal grafts in huntington disease patients. Ann Neurol 2014; 76: 31-42.
7. Cisbani G, Freeman TB, Soulet D, Saint-Pierre M, Gagnon D, Parent M, et al. Striatal allografts in patients with Huntington's disease: impact of diminished astrocytes and vascularization on graft viability. Brain 2013; 136: 433-443.
8. Caparros-Lefebvre D, Kerdraon O, Devos D, Dhaenens CM, Blum D, Maurage CA, et al. Association of corticobasal degeneration and Huntington's disease: can Tau aggregates protect Huntingtin toxicity? Mov Disord 2009; 24: 1089-90. doi: 10.1002/mds.22204.
9. Davis MY, Keene CD, Jayadev S, Bird T. The co-occurrence of Alzheimer's disease and Huntington's disease: a neuropathological study of 15 elderly Huntington's disease subjects. J Huntingtons Dis 2014; 3: 209-17. doi: 10.3233/JHD-140111.
10. de Silva R, Lashley T, Gibb G, Hanger D, Hope A, Reid A, et al. Pathological inclusion bodies in tauopathies contain distinct complements of tau with three or four microtubule-binding repeat domains as demonstrated by new specific monoclonal antibodies. Neuropathol Appl Neurobiol 2003; 29: 288-302.
11. Fernández-Nogales M, Cabrera JR, Santos-Galindo M, Hoozemans JJ, Ferrer I, Rozemuller AJ, et al. Huntington's disease is a four-repeat tauopathy with tau nuclear rods. Nat Med 2014; 20: 881-5.
12. Gerson JE, Kayed R. Formation and propagation of tau oligomeric seeds. Front Neurol 2013; 17; 4: 93.
13. Goedert M, Jakes R. Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and effects on tubulin polymerization. EMBO J 1990; 9: 4225-30.
14. Goedert M, Spillantini MG, Cairns NJ, Crowther RA. Tau proteins of Alzheimer paired helical filaments: abnormal phosphorylation of all six brain isoforms. Neuron 1992; 8: 159-68.
15. Goedert M, Spillantini MG, Potier MC, Ulrich J, Crowther RA. Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four tandem repeats: differential expression of tau protein mRNAs in human brain. EMBO J 1989; 8: 393-9.
16. Goedert M, Wischik CM, Crowther RA, Walker JE, Klug A. Cloning and sequencing of the cDNA encoding a core protein of the paired helical filament of Alzheimer disease: identification as the microtubule-associated protein tau. Proc Natl Acad Sci USA 1988; 85: 4051-5.
17. Goris A, Williams-Gray CH, Clark GR, Foltynie T, Lewis SJ, Brown J, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007; 62: 145-53.
18. Gratuze M, Noël A, Julien C, Cisbani G, Milot-Rousseau P, Morin F, et al. Tau hyperphosphorylation and deregulation of calcineurin in mouse models of Huntington's disease. Hum Mol Genet 2015; 24: 86-99.
19. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986; 83: 4913-17.
20. Gusella JF, Wexler NS, Conneally PM, Naylor SL, Anderson MA, Tanzi RE, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature 1983; 306: 234-8.
21. Hanger DP, Gibb GM, de Silva R, Boutajangout A, Brion JP, Revesz T, et al. The complex relationship between soluble and insoluble tau in tauopathies revealed by efficient dephosphorylation and specific antibodies. FEBS Lett 2002; 531: 538-42.
22. Hernández F, Avila J. Tau aggregates and tau pathology. J Alzheimers Dis 2008; 14: 449-52.
23. Ho AK, Sahakian BJ, Robbins TW, Barker RA, Rosser AE, Hodges JR. Verbal fluency in Huntington's disease: a longitudinal analysis of phonemic and semantic clustering and switching. Neuropsycologia 2002; 40: 1277-84.
24. Houlden H, Baker M, Morris HR, MacDonald N, Pickering-Brown S, Adamson J, et al. Corticobasal degeneration and progressive supranuclear palsy share a common tau haplotype. Neurology 2001; 56: 1702-6.
25. Huntington Study GroupUnified Huntington's disease rating scale: reliability and consistency. Huntington Study Group. Mov Disord 1996; 11: 136-42.
26. Jellinger KA. Alzheimer-type lesions in Huntington's disease. J Neural Transm 1998; 105: 787-99.
27. Kosik KS, Joachim CL, Selkoe DJ. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. Proc Natl Acad Sci USA 1986; 83: 4044-8.
28. Novak MJ, Tabrizi SJ. Huntington's disease: clinical presentation and treatment. Int Rev Neurobiol 2011; 98: 297-23.
29. Orth M, European Huntington's Disease NetworkHandley OJ, Schwenke C, Dunnett S, Wild EJ, et al. Observing Huntington's disease: the European Huntington's Disease Network's REGISTRY. J Neurol Neurosurg Psychiatry 2011; 82: 1409-12.
30. Ranen NG, Stine OC, Abbott MH, Sherr M, Codori AM, Franzet ML, et al. Anticipation and instability of IT-15 (CAG)n repeats in parentoffspring pairs with Huntington disease. Am J Hum Genet 1995; 57: 593-602.
31. Ready RE, Mathews M, Leserman A, Paulsen JS. Patient and caregiver quality of life in Huntington's disease. Mov Disord 2008; 23: 721-26.
32. Sergeant N, Delacourte A, Buée L. Tau protein as a differential biomarker of tauopathies. Biochim Biophys Acta 2005; 1739: 179-97.
33. Spillantini MG, Goedert M. Tau pathology and neurodegeneration. Lancet Neurol 2013; 12: 609-22.
34. Stefansson H, Helgason A, Thorleifsson G, Steinthorsdottir V, Masson G, Barnard J, et al. A common inversion under selection in Europeans. Nat Genet 2005; 37: 129-37.
35. The Huntington's Disease Collaborative Research Group, A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 1993; 72: 971-83.
36. Vonsattel JP, DiFiglia M. Huntington disease. J Neuropathol Exp Neurol 1998; 57: 369-84.
37. Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP Jr. Neuropathological classification of Huntington's disease. J Neuropathol Exp Neurol 1985; 44: 559-77.
38. Williams-Gray CH, Evans JR, Goris A, Foltynie T, Ban M, Robbins TW, et al. The distinct cognitive syndromes of Parkinson's disease: 5 years follow-up of the CamPaIGN cohort. Brain 2009; 132: 2958-69.
39. Wood JC, Mirra SS, Pollock NJ, Binder LI. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (-). Proc Natl Acad Sci USA 1986; 83: 4040-3.
40. Yin X, Jin N, Gu J, Shi J, Zhou J, Gong CX, et al. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A) modulates serine/arginine-rich protein 55 (SRp55)-promoted Tau exon 10 inclusion. J Biol Chem 2012; 287: 30497-506.
41. Yoshida M. Cellular tau pathology and immunohistochemical study of tau isoforms in sporadic tauopathies. Neuropathology 2006; 26: 457-70.
42. Zuccato C, Valenza M, Cattaneo E. Molecular mechanisms and potential therapeutical targets in Huntington's disease. Physiol Rev 2010; 90: 905-81.